Beyond ipilimumab: new approaches target the immunological synapse.

  title={Beyond ipilimumab: new approaches target the immunological synapse.},
  author={Ken Garber},
  journal={Journal of the National Cancer Institute},
  volume={103 14},
T he March 25 approval of ipilimumab (Yervoy) by the U.S. Food and Drug Administration was a milestone for the embattled field of cancer immuno-therapy. As the first agent to increase overall survival in a phase III melanoma trial, ipilimumab appeared to vindicate the immune surveillance hypothesis of cancer first proposed in 1957. That hypothesis, which posits that the immune system plays a key role in keeping tumors in check, gave rise to hopes that boosting the immune system could eradicate… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…